News and Press Releases
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...
Category: Drug Discovery
Posted: June 10, 2024
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK
Kite Receives European Medicines Agency Approval of Safety Monitoring Variation for CAR T-Cell Therapy Portfolio
In-hospital patient monitoring for adverse events reduced from ten to seven days following CAR T-cell therapy infusion 6 June 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 6, 2024
MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid...
Category: Biotechnology, Manufacturing and Packing, Pharmaceutical
Posted: June 6, 2024
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting
2 June 2024 -- Utrecht, The Netherlands and Massachusetts, US -- Merus NV, a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced updated interim clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 2, 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
23 May 2024 -- Tokyo, Japan -- Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American...
Category: Clinical Trials, Drug Discovery
Posted: May 23, 2024
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis
China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has...
Category: Biotechnology, Clinical Trials
Posted: May 22, 2024
KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy
Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma...
Category: Clinical Trials, Pharmaceutical
Posted: May 14, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Gilead Sciences Appoints Peter Wickersham to Vice-President and General Manager in the UK and Ireland
7 May 2024 -- London, UK -- Gilead Sciences announced today the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
CARVYKTI▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the EC for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from...
Category: Biotechnology, Clinical Trials
Posted: April 22, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
